Dive Brief: NeoGenomics has exercised its option to buy the remaining stake in Inivata for $390 million, positioning it to challenge for the liquid biopsy market. NeoGenomics expects the deal to close in the midlle of June. The takeover will give NeoGenomics full ownership of InVisionFirst-Lung, a lung cancer panel that it already commercializes in the U.S., and the residual disease assay RaDaR. William Blair analysts welcomed the deal, noting that NeoGenomics got a good price by setting the buyout fee when it invested $25 million in Inivata last year. Dive Insight: Inivata is a University of Cambridge spinout with two liquid biopsy assays. NeoGenomics secured the rights to commercialize non-small cell lung cancer assay InVisionFirst-Lung in the U.S. last year. That test accounts for most of the $5 million in sales NeoGenomics expects Inivata to generate this year.